The Relationship of Ki-67 Over-expression with Clinicopathological Prognostic Parameters in Invasive Breast Carcinomas
Yıl: 2021 Cilt: 36 Sayı: 4 Sayfa Aralığı: 415 - 422 Metin Dili: İngilizce DOI: 10.5505/tjo.2021.2851 İndeks Tarihi: 15-06-2022
The Relationship of Ki-67 Over-expression with Clinicopathological Prognostic Parameters in Invasive Breast Carcinomas
Öz: OBJECTIVE
Immunohistochemical Ki-67 index is a useful method to determine the prognosis. We aimed to evaluate
the association of Ki-67 score, using 14% and 20% cut-off values, with clinicopathological parameters
in invasive breast carcinomas.
METHODS
Pathology reports of 162 females were retrospectively reviewed and parameters including age, menopausal status, multifocality/multicentricity (MF/MC), tumor size, histological type, grade, lymphovascular invasion (LVI), perineural invasion, axillary lymph node status, ER, PR, HER2 status, Ki-67 index,
and molecular subtype were recorded. The cases were grouped according to two separate Ki-67 cut-off
values (high: ≥14% and ≥20%, low <14%, and <20%). Ki-67 score was compared with other clinicopathological parameters statistically using Chi-square test.
RESULTS
When the Ki-67 score was grouped according to 14% or 20% cut-off values, it was found to be associated with similar clinicopathological parameters. There was a significant correlation between high Ki-67
score and high grade (p<0.001, p<0.001), LVI (p=0.002, p=0.022), ER negativity (p=0.001, p<0.001).
When ER expression was grouped as negative, low positive and positive, similar results were obtained
(p=0.003, p=0.001). There was a significant association between Ki-67 score and molecular subtypes
(p<0.001, p<0.001): Ki-67 score was higher in cases that belong to Luminal B subtype and lower in cases
that belong to Luminal A in comparison to others. Ki-67 score had no association with age, menopausal
status, MF/MC, tumor size, perineural invasion, axillary lymph node involvement, PR, and HER2 status.
CONCLUSION
Standardization of interpretation of Ki-67 proliferative index and cut-off value for scoring will improve
the demonstration of the prognostic signification of Ki-67 in invasive breast carcinomas.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Penault-Llorca F, Radosevic-Robin N. Ki-67 assessment in breast cancer: An update. Pathology 2017;49(2):166–71.
- 2. Ermiah E, Buhmeida A, Abdalla F, Khaled BR, Salem N, Pyrhönen S, et al. Prognostic value of proliferation markers: Immunohistochemical Ki-67 expression and cytometric s-phase fraction of women with breast cancer in Libya. J Cancer 2012;3:421–31.
- 3. Haroon S, Hashmi AA, Khurshid A, Kanpurwala MA, Mujtuba S, Malik B, et al. Ki-67 index in breast cancer: Correlation with other prognostic markers and potential in Pakistani patients. Asian Pac J Cancer Prev 2013;14(7):4353–8.
- 4. Aman NA, Doukoure B, Koffi KD, Koui BS, Traore ZC, Kouyate M, et al. Immunohistochemical evaluation of Ki-67 and comparison with clinicopathologic factors in breast carcinomas. Asian Pac J Cancer Prev 2019;20(1):73–9.
- 5. Sun J, Chen C, Wei W, Zheng H, Yuan J, Tu YI, et al. Associations and indications of Ki-67 expression with clinicopathological parameters and molecular subtypes in invasive breast cancer: A population-based study. Oncol Lett. 2015;10(3):1741–8.
- 6. Kamranzadeh H, Ardekani RM, Kasaeian A, Sadighi S, Maghsudi S, Jahanzad I, et al. Association between Ki-67 expression and clinicopathological features in prognosis of breast cancer: A retrospective cohort study. J Res Med Sci 2019;24:30.
- 7. Elkablawy MA, Albasri AM, Mohammed RA, Hussainy AS, Nouh MM, Alhujaily AS. Ki-67 expression in breast cancer. Correlation with prognostic markers and clinicopathological parameters in Saudi patients. Saudi Med J 2016;37(2):137–41.
- 8. Hortobagyi GN, Connolly JL, D’Orsi CJ, Edge SB, Mittendorf EA, Rugo HS, et al. Breast. In: Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, et al, editors. AJCC Cancer Staging Manual. 8th ed. Switzerland: Springer International Publishing AG; 2017. p. 589–628.
- 9. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. WHO Classification of Tumours of the Breast. 4th ed. Lyon, France: IARC Press; 2012.
- 10.Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991;19(5):403– 10.
- 11.Fitzgibbons PL, Connolly JL. Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. CAP Guideline; 2021. Available at: https://www.documents.cap.org/ protocols/Breast.Bmk_1.4.1.0.REL_CAPCP.pdf. Accessed Aug 12, 2021.
- 12.Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, Panel Members. Strategies for subtypes--dealing with the diversity of breast cancer: Highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 2011;22(8):1736–47.
- 13.Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol 2013;24(9):2206–23.
- 14.Pérez-López ME, García-Gómez J, Alves MT, Paradela A, García-Mata J, García-Caballero T. Ki-67 is a prognostic marker for hormone receptor positive tumors. Clin Transl Oncol 2016;18(10):996–1002.
- 15.Jain P, Doval DC, Batra U, Goyal P, Bothra SJ, Agarwal C, et al. Ki-67 labeling index as a predictor of response to neoadjuvant chemotherapy in breast cancer. Jpn J Clin Oncol 2019;49(4):329–38.
- 16.Viale G, Hanlon Newell AE, Walker E, Harlow G, Bai I, Russo L, et al. Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes. Breast Cancer Res Treat 2019;178(2):451–8.
- 17.Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ, Panel Members. Thresholds for therapies: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009;20(8):1319–29.
- 18.Kinoe H, Yamanouchi K, Kuba S, Morita M, Sakimura C, Kanetaka K, et al. Discordance of hormone receptor, human epidermal growth factor receptor-2, and Ki-67 between primary breast cancer and synchronous axillary lymph node metastasis. J BUON 2018;23(7):60–6.
- 19.Dedić Plavetić N, Jakić-Razumović J, Kulić A, Sirotković-Skerlev M, Barić M, Vrbanec D. Prognostic value of ki-67 in breast carcinoma: Tissue microarray method versus whole section analysis-potentials and pitfalls. Pathol Oncol Res 2015;21(2):315–24.
| APA | demir h, Ozturk T, Gülle B, ilvan S (2021). The Relationship of Ki-67 Over-expression with Clinicopathological Prognostic Parameters in Invasive Breast Carcinomas. , 415 - 422. 10.5505/tjo.2021.2851 |
| Chicago | demir hale,Ozturk Tulin,Gülle Buğra Taygun,ilvan Sennur The Relationship of Ki-67 Over-expression with Clinicopathological Prognostic Parameters in Invasive Breast Carcinomas. (2021): 415 - 422. 10.5505/tjo.2021.2851 |
| MLA | demir hale,Ozturk Tulin,Gülle Buğra Taygun,ilvan Sennur The Relationship of Ki-67 Over-expression with Clinicopathological Prognostic Parameters in Invasive Breast Carcinomas. , 2021, ss.415 - 422. 10.5505/tjo.2021.2851 |
| AMA | demir h,Ozturk T,Gülle B,ilvan S The Relationship of Ki-67 Over-expression with Clinicopathological Prognostic Parameters in Invasive Breast Carcinomas. . 2021; 415 - 422. 10.5505/tjo.2021.2851 |
| Vancouver | demir h,Ozturk T,Gülle B,ilvan S The Relationship of Ki-67 Over-expression with Clinicopathological Prognostic Parameters in Invasive Breast Carcinomas. . 2021; 415 - 422. 10.5505/tjo.2021.2851 |
| IEEE | demir h,Ozturk T,Gülle B,ilvan S "The Relationship of Ki-67 Over-expression with Clinicopathological Prognostic Parameters in Invasive Breast Carcinomas." , ss.415 - 422, 2021. 10.5505/tjo.2021.2851 |
| ISNAD | demir, hale vd. "The Relationship of Ki-67 Over-expression with Clinicopathological Prognostic Parameters in Invasive Breast Carcinomas". (2021), 415-422. https://doi.org/10.5505/tjo.2021.2851 |
| APA | demir h, Ozturk T, Gülle B, ilvan S (2021). The Relationship of Ki-67 Over-expression with Clinicopathological Prognostic Parameters in Invasive Breast Carcinomas. Türk Onkoloji Dergisi, 36(4), 415 - 422. 10.5505/tjo.2021.2851 |
| Chicago | demir hale,Ozturk Tulin,Gülle Buğra Taygun,ilvan Sennur The Relationship of Ki-67 Over-expression with Clinicopathological Prognostic Parameters in Invasive Breast Carcinomas. Türk Onkoloji Dergisi 36, no.4 (2021): 415 - 422. 10.5505/tjo.2021.2851 |
| MLA | demir hale,Ozturk Tulin,Gülle Buğra Taygun,ilvan Sennur The Relationship of Ki-67 Over-expression with Clinicopathological Prognostic Parameters in Invasive Breast Carcinomas. Türk Onkoloji Dergisi, vol.36, no.4, 2021, ss.415 - 422. 10.5505/tjo.2021.2851 |
| AMA | demir h,Ozturk T,Gülle B,ilvan S The Relationship of Ki-67 Over-expression with Clinicopathological Prognostic Parameters in Invasive Breast Carcinomas. Türk Onkoloji Dergisi. 2021; 36(4): 415 - 422. 10.5505/tjo.2021.2851 |
| Vancouver | demir h,Ozturk T,Gülle B,ilvan S The Relationship of Ki-67 Over-expression with Clinicopathological Prognostic Parameters in Invasive Breast Carcinomas. Türk Onkoloji Dergisi. 2021; 36(4): 415 - 422. 10.5505/tjo.2021.2851 |
| IEEE | demir h,Ozturk T,Gülle B,ilvan S "The Relationship of Ki-67 Over-expression with Clinicopathological Prognostic Parameters in Invasive Breast Carcinomas." Türk Onkoloji Dergisi, 36, ss.415 - 422, 2021. 10.5505/tjo.2021.2851 |
| ISNAD | demir, hale vd. "The Relationship of Ki-67 Over-expression with Clinicopathological Prognostic Parameters in Invasive Breast Carcinomas". Türk Onkoloji Dergisi 36/4 (2021), 415-422. https://doi.org/10.5505/tjo.2021.2851 |
